SMIM8

Across TCGA pan-cancer cohorts, SMIM8 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMIM8 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SMIM8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMIM8 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where SMIM8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.247	1.000	.002	39	view →
LSCC	OS	Median	All	0.923	0.708	.002	8	view →
UCEC	DFS	Tertile	III,IV	0.419	1.000	.040	4	view →
LUAD	OS	Tertile	All	0.461	1.000	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMIM8–PDAC (DFS)

Open the PDAC breakdown →